Naslov
Incidence of hypokalemia during therapy with abirateron acetate - real clinical practice data
(Incidence of hypokalemia during therapy with abirateron acetate - real clinical practice data)

Autori
Vazdar, Ljubica ; Linarić, Petra ; Pavlović, Mirjana ; Tečić Vuger, Ana ; Šeparović, Robert ; Jurić, Andreja

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Libri Oncologici : Croatian Journal of Oncology / - , 2022, 55-55

Skup
1st Croatian virtual congress of oncology pharmacy

Mjesto i datum
Online, 07.10.2021. - 10.10.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
abirateron acetate, metastatic castration-resistant prostate cancer, hypokalemia

Sažetak
Abirateron acetate (AA) selectively inhibits the CYP17 enzyme resulting in a decrease in androgen synthesis in the adrenal glands, testicles and prostate tissue. Inhibition of CYP17 reduces serum cortisol levels and increases ACTH secretion through negative feedback loop, which can lead to mineralocorticoid excess and cause hypokalemia, fluid retention and hypertension. Results show that in real clinical practice, AA therapy with prednisone coadministration does not lead to a significant suppression of serum cortisol levels and recurrent meneralocorticoid excess. On the other hand, a possible influence on the low incidence of hypokalemia is an angiotensin converting enzyme inhibitor (ACEi) therapy that was present in 13 (36%) patients due to comorbidity. In view of possible more severe forms of hypokalemia, especially in patients after docetaxel therapy and coadministration of ACEi and/or diuretics, serum potassium value should be monitored according to recommendations.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA